Data updated: Nov 8, 2026
Flumist, Flumist Quad (influenza vaccine live, intranasal) · AstraZeneca
Approved 2003-06-17
1
Indication
--
Phase 3 Trials
23
Years on Market
Details
- Status
- Prescription
- First Approved
- 2003-06-17
- Revenue
- $146M (Q3-2026)
- Routes
- Nasal
- Dosage Forms
- Suspension
Companies
Website: ↗
Flumist, Flumist Quad Approval History
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2003 to 2003
Jun 2003 ORIGINAL
Update · CBER biologic (Purple Book)
What Flumist, Flumist Quad Treats
1 FDA approvalsOriginally approved for its first indication in 2003 .
- Other (1)
Other
(1 approval)- • Approved indication (Jun 2003)
AstraZeneca's other novel FDA approvals
Other CDER-designated drugs from the same sponsor (2016–2025).
TRUQAP
2023 CAPIVASERTIB
3 designations
BEYFORTUS
2023 NIRSEVIMAB-ALIP
1 designation
WAINUA (AUTOINJECTOR)
2023 EPLONTERSEN SODIUM
1 designation
IMJUDO
2022 TREMELIMUMAB-ACTL
1 designation
SAPHNELO
2021 ANIFROLUMAB-FNIA
2 designations
TEZSPIRE
2021 TEZEPELUMAB-EKKO
2 designations
KOSELUGO
2020 SELUMETINIB
4 designations
LOKELMA
2018 SODIUM ZIRCONIUM CYCLOSILICATE
CALQUENCE
2017 ACALABRUTINIB MALEATE
4 designations
FASENRA
2017 BENRALIZUMAB
IMFINZI
2017 DURVALUMAB
3 designations
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
Flumist, Flumist Quad FDA Label Details
Pro Intelligence Preview
Deep insights for Flumist, Flumist Quad
Revenue Insights
- • Q3-2026: $146M
- • Historical trend analysis
Patent Timeline
- • Patent expiration dates
- • Generic/biosimilar risk
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • Competitor tracking
- • Same target/indication analysis
Unlock Full Intelligence
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.